NASDAQ: LEGNLegend Biotech Corp Stock
$33.11-0.72 (-2.13%)
Updated Sep 12, 2025
LEGN Price
$33.11
Fair Value Price
N/A
Market Cap
$6.11B
52 Week Low
$27.34
52 Week High
$52.31
P/E
-18.6x
P/B
5.9x
P/S
8.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$796.84M
Earnings
-$325.33M
Gross Margin
62.5%
Operating Margin
-35.56%
Profit Margin
-40.8%
Debt to Equity
0.63
Operating Cash Flow
-$304M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LEGN Overview
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LEGN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
LEGN
Ranked#117 of 476
Ranked#117 of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $37.96 | A | |
| $7.91 | A |
Be the first to know about important LEGN news, forecast changes, insider trades & much more!
LEGN News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LEGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LEGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LEGN is poor value based on its book value relative to its share price (5.9x), compared to the US Biotechnology industry average (4.65x)
P/B vs Industry Valuation
LEGN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LEGN due diligence checks available for Premium users.
Valuation
LEGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-18.6x
Industry
-97.08x
Market
36.98x
LEGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.9x
Industry
4.65x
LEGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LEGN's financial health
Profit margin
Revenue
$255.1M
Net Income
-$125.4M
Profit Margin
-49.2%
LEGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LEGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.7B
Liabilities
$654.4M
Debt to equity
0.63
LEGN's short-term assets ($1.25B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LEGN's short-term assets ($1.25B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LEGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LEGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$32.1M
Investing
-$165.5M
Financing
-$990.0k
LEGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LEGN vs Biotech Stocks
Legend Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.